Good find. If Shattuck is successful I expect Takeda will buy them up as they did with ARIAD($5.2 Billion). And as Shattuck's technology is at least partly exclusively licensed from Heat...I would expect they will also be watching Heat. Takeda is a very large international Japanese pharma...which was relatively weak in oncology...hence their purchase of ARIAD, collaboration with Shattuck and IMO potential interest in Heat! Along with the 5 big pharmas who have checkpoint inhibitors who need help to improve efficacy and safety...we can add Takeda who are clearly seeking to make up their oncology deficit.
"The refusal of the real is the number one dogma of our time" Rene Girard